UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 5, 2017

APTEVO THERAPEUTICS INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware	**001-37746**	**81-1567056**
(State or Other Jurisdiction of Incorporation	**(Commission File Number)**	**(IRS Employer Identification No.)**

2401 4th Avenue, Suite 1050 **Seattle, Washington**	**98121**
(Address of Principal Executive Offices)	**(Zip Code)**

Registrant's telephone number, including area code: (206) 838-0500

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Aptevo Therapeutics Inc. ("Aptevo") has prepared investor presentation materials with information about Aptevo, which it intends to use as part of investor presentations. A copy of the investor presentation materials to be used by management for presentations is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 8.01 Other Events

On January 5, 2017, Aptevo received a $20.0 million cash payment from Emergent BioSolutions Inc. ("Emergent") pursuant to the terms of a Non-Negotiable Promissory Note from Emergent to Aptevo, dated July 29, 2016, entered into in connection with the spin-off of Aptevo from Emergent in August 2016.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

APTEVO THERAPEUTICS INC.

Date: January 6, 2017

By: /s/ Shawnte Mitchell
Shawnte Mitchell, Secretary, Vice President and General Counsel

EXHIBIT INDEX

Exhibit Number	Exhibit Description
99.1	Presentation of Aptevo Therapeutics Inc. dated January 2017

Exhibit 99.1

January 2017

Aptevo Therapeutics

Investor Presentation

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance, product portfolio, product sales, capabilities and any other statements containing the words "believes", "expects", "anticipates", "intends", "plans", "forecasts", "estimates" and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development, regulatory approvals or expenditures are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this presentation, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on Aptevo's business operations, assets or financial results as a result of the separation; a deterioration in the business or prospects of Aptevo; adverse developments in Aptevo's customer-base or markets; our ability to enter into and maintain selective collaboration and partnership arrangements; the timing of and our ability to achieve milestones in collaboration and partnership contracts; our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; and our commercialization, marketing and manufacturing capabilities and strategy and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission, including Aptevo's most recent Quarterly Report on Form 10-Q, as filed on November 14, 2016.

The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

AGENDA

Leadership in Bispecific Antibody Development

- Aptevo Today
- ADAPTIR – Differentiated Bispecific Platform
- Summary

Aptevo: At a Glance

Focus	Oncology/Hematology
Commercial Products	4
Product Pipeline	Clinical: 2 Preclinical: Multiple
Platform Technologies	ADAPTIR™
Employees	~150
Headquarters	Seattle, WA
2016 Revenue (9/30/16)	$27.5M
2015 Revenue	$33.6M
Cash Position	$54M 12/31/2016 (approx.) $20M Emergent payment (1/5/17) $15M MidCap 2nd tranche option

Leading Oncology Platform

- Innovative ADAPTIR platform technology utilizing a promising approach in the highly attractive immuno-oncology field

Leveraging Technology

- Targeted investments in bispecific ADAPTIR therapeutics

Strong IP Estate

- Intend to own or exclusively license patent rights for entire product portfolio

Executive Leadership

Senior Management

Marvin White – President & CEO
Former Emergent Director; Former CFO, St. Vincent's Health; Former Exec. Director & CFO, Lilly USA

Jeff Lamothe – SVP, CFO
Former Emergent VP, Finance; Former CFO, Cangene Corporation

Randy Maddux – SVP, Operations
Former VP, Global Mfg & Supply, GSK;
Former VP, Mfg Ops & Quality, Human Genome Sciences

Dr. Scott Stromatt – SVP, CMO
Former Emergent SVP, CMO; Former CMO, Trubion

Dr. Jane Gross – SVP, CSO
Emergent VP, Research/Non-Clinical Development;
Former VP Immunology Research ZymoGenetics Inc.

Mike Adelman – VP, Commercial Ops.
Former Emergent VP, Commercial Operations; Former, VP Commercial Operations, Cangene Corporation

Shawnte Mitchell – VP, Gen'l Counsel/HR
Former Emergent VP, Associate General Counsel

Board of Directors

Marvin White
Former Emergent Director; Former CFO, St. Vincent's Health; Former Exec. Director & CFO, Lilly USA

Fuad El-Hibri
Founder, Executive Chairman, Emergent BioSolutions

Daniel Abdun-Nabi
President & CEO, Emergent BioSolutions

Grady Grant, III
Mead Johnson Nutrition; Eli Lilly & Co.

Zsolt Harsanyi, Ph.D.
N-Gene Research Labs; Exponential Biotherapies; Porton Int'l

Barbara Lopez Kunz
DIA; Battelle; Thermo Fisher Scientific; ICI/Uniqema

John Niederhuber, M.D.
Inova Translational Medicine Institute; NCI; Johns Hopkins Univ.

Deep R&D, Commercial and Financial Expertise and Experience

Our Strategy

1. **Advance novel ADAPTIR product candidates, primarily in immuno-oncology**
2. **Expand collaborations and partnerships**
3. **Maximize cash flow from commercial portfolio to support R&D funding**

Robust and Diversified Product Portfolio

Product/Candidate	Technology	Indication	Pre-Clinical	Clinical Development Stage			Marketed	Milestones/Highlights
				Phase I	Phase II	Phase III		
IXINITY	*Recombinant Protein*	*Hemophilia B*						$1.0M WW in 2015 $7.0M (9/30/2016)
WinRho	*Hyper Immune*	*ITP*						$14.2M WW in 2015 $10.6M (9/30/2016)
HepaGam B	*Hyper Immune*	*HBV*						$10.3M WW in 2015 $7.1M (9/30/2016)
VARIZIG	*Hyper Immune*	*Varicella*						$2.3M WW in 2015 $2.8M (9/30/2016)
Otlertuzumab	*ADAPTIR Monospecific*	*CLL*						Executing Phase 1b combination study
MOR209/ES414*	*ADAPTIR Bispecific RTCC*	*mCRPC Immuno-oncology*						Executing Phase 1 clinical trial
ROR1	*ADAPTIR Bispecific RTCC*	*Hematological, Solid Tumor Malignancies*						Preclinical in vitro and in vivo POC, developing lead candidate
Multiple ADAPTIR Candidates	*ADAPTIR Bispecific*	*Hematological, Solid Tumor Malignancies*						Multiple RTCC candidates and ADAPTIR with novel MOA
ES210	*ADAPTIR Targeted cytokine*	*IBD*						Preclinical POC in IBD, CHO production cell line

RTCC – Redirected T-Cell Cytotoxicity

** Partnered with MorphoSys AG*

Commercial Portfolio – Hyperimmune Platform

WINRHO SDF

US: [Rho (D) Immune Globulin Intravenous (Human)] Canada: (Rho(D) Immune Globulin (Human) for injection)

Immune Thrombocytopenic Purpura (ITP) and suppression of Rhesus (Rh) isoimmunization

HEPAGAM B

US: [Hepatitis B Immune Globulin Intravenous (Human)] Canada: (Hepatitis B Immune Globulin (Human) Injection)

Prevention of hepatitis B recurrence following liver transplantation in HBsAg-positive patients and post exposure prophylaxis after acute hepatitis B exposure



VARIZIG®

US: VARIZIG® [Varicella Zoster Immune Globulin (Human)] Canada: VariZIG® (Varicella Zoster Immune Globulin (Human))

Post-exposure prophylaxis of varicella zoster in high risk individuals

- Mature, well established products
- Serve niche or ultra niche markets
- Provide stable, dependable revenue base
  - Mitigate cash burn
  - Support R&D spend
  - $25-30M annually (approx.)
  - $10M annual cash flow (approx.)
- Modest opportunity for ex-US growth

Commercial Portfolio – Recombinant Platform

IXINITY®

[coagulation factor IX (recombinant)]

An intravenous recombinant human coagulation factor IX therapeutic for use in patients with Hemophilia B

- Strong growth opportunity
- WW rights owned by Aptevo
- U.S. launch mid-2015
- Target market:
  - Hemophilia B
  - Young, active adults (individuals 12+ years)
- Good acceptance in the market
- Opportunity to explore ex-US launch with partner
- Bulk drug substance manufacturing challenge resolved
- Anticipate Q1 2017 stock out followed by market re-entry in Q2 2017

AGENDA

Leadership in Bispecific Antibody Development

- Aptevo Today
- ADAPTIR – Differentiated Bispecific Platform
- Summary

ADAPTIR – A Differentiated Bispecific Antibody Platform Technology



MODULAR AND FLEXIBLE

- Monospecific and bispecific formats
- Flexible design supports reproducible generation of bispecifics with potent activity

MULTIPLE MECHANISMS OF ACTION

- Redirected T-Cell Cytotoxicity (RTCC)
- Target receptors that stimulate or inhibit immunes responses
- Target cytokines to modify the immune environment

EXCELLENT MANUFACTURING PROPERTIES

- Single chain facilitates ease of CHO cell production
- Antibody backbone increases stability
- Standard manufacturing process with high yields and purity

ANTIBODY-LIKE HALF LIFE

- Half-life up to 12 days

Expertise in Bispecific Antibodies Facilitates Rapid Development from Concept to Clinic

Aptevo Therapeutics



ADAPTIR RTCC Mechanism of Action

ADAPTIR Bispecific Molecules Mediate RTCC: Potent Immunotherapeutic for Cancer



ADAPTIR RTCC Therapeutics
Key Advantages vs Other RTCC Bispecifics

Highly potent	**Potent target-dependent cytotoxicity in preclinical studies demonstrated for numerous tumor antigens**
Longer Half Life	**Antibody-like half-life obtained in preclinical studies; up to 12 days**
Reduced Toxicity	**Low levels of cytokines produced after engagement of target cells shown in preclinical studies**
Improved Convenience	**"Off the shelf" technology vs "cell-based" therapies Better COGS, ability to control dose**

ADAPTIR RTCC Bispecifics are Differentiated From Other Bispecific Formats

ADAPTIR™ RTCC molecules are more potent in preclinical studies compared to other bispecific platforms





ADAPTIR RTCC - More Potent than Bispecifics in Heterodimer Format Targeting the Same Antigen

Redirected T-cell Tumor Lysis assay using unstimulated T cells (20 hr Cr_{-51} Release Assay)



ADAPTIR Bispecifics Are More Potent Compared to Heterodimeric Antibody Formats

- Higher levels of maximal specific lysis of tumor cells
- Lower EC_{50} values

Protein	EC_{50}
ADAPTIR	17.2 pM
het scFv-Fc	66.8 pM
Het Fab/scFv-Fc	136 pM

MOR209/ES414 - More Potent Than BiTE® (scFv-scFv Format)[1]



MOR209/ES414 (ADAPTIR molecule)

αPSMA x αCD3 BiTE scFv-scFv

Protein	EC_{50}
MOR209/ES414	2.7 ± 0.6 pM
scFv-scFv	99 ± 10 pM

Assay utilizes MDA-PCa-2b target cells and primary T cells; 4 hr timepoint

1. Same amino acid sequence as AMG212/BAY2010112/pasotuxizumab (WHO Drug Information, Vol. 28, No. 2, 2014, pg 251-252)

ADAPTIR Clinical Pipeline

Product Candidate	Technology	Indication	Pre-Clinical	Clinical Development Stage			Milestones Highlights
				Phase I	Phase II	Phase III	
Otlertuzumab	*ADAPTIR Monospecific*	*CLL*					Executing Phase 1b combination study
MOR209/ES414*	*ADAPTIR Bispecific RTCC*	*mCRPC Immuno-oncology*					Executing Phase 1 clinical trial

RTCC – Redirected T-Cell Cytotoxicity

**** Partnered with MorphoSys AG***

Clinical Candidate – otlertuzumab (CLL)



αCD37 scFv



Human IgG_1 Fc

Description

- Humanized monospecific protein therapeutic
- Targets CD37 and its signaling pathway involved in B-cell malignancies
- Built on ADAPTIR (modular protein therapeutic) platform
- Demonstrated anti-tumor activity
- Prolonged serum half-life (mouse /NHP) vs antibody fragments

Partnering

- 100% owned by Aptevo
- Actively pursuing potential partnership opportunities

Development Status

- 253 subjects treated to date; appears safe and well tolerated
- Ongoing: Phase 2 study for chronic lymphocytic leukemia (CLL)
  - Combination with ibrutinib
  - Preliminary data read-out anticipated in H2 2017
- Multiple clinical trial data published, establishing clinical proof-of-concept
  - PHASE 2 STUDY (16201): Combination of otlertuzumab and bendamustine in patients with relapsed CLL produced significantly higher response rates and longer progression free survival than bendamustine alone
  - PHASE 1b STUDY (16009): Combination of otlertuzumab and rituximab in patients with previously untreated CLL was active and well tolerated

Otlertuzumab + Bendamustine Significantly Increased Overall Response Rate



Otlertuzumab + Bendamustine Significantly Increased Progression Free Survival



Clinical Candidate – MOR209/ES414 (mCRPC)



Anti-PSMA



Anti-CD3

Description

- Humanized bispecific protein therapeutic
- Targets PSMA and CD3, a component of the T-cell receptor
- Demonstrated redirection of T-cells to kill tumor cells expressing PSMA in vitro and in vivo
- Prolonged serum half-life (mouse/NHP) vs antibody fragments

Partnering

- Co-development/Co-commercialization partnership with MorphoSys AG established August 2014

Development Status

- Open-label Phase 1 continuous infusion study underway (U.S. & Australia)
- Safety, tolerability, and clinical activity endpoints
- In patients with metastatic castration-resistant prostate cancer (mCRPC) to be conducted in 2 stages
  - Stage 1: Primary Objective -- identify MTD administered intravenously. Secondary Objectives -- evaluate tolerability, PK, PD, immunogenicity, cytokine response, and clinical activity
  - Stage 2: Primary Objective -- evaluate clinical activity in patients that have or have not received prior chemotherapy
- Preliminary data read-out anticipated mid-2017

MOR209/ES414 Delays Tumor Growth and Improves Survival (Subcutaneous Xenograft Model)

Delay of Tumor Growth



Improved Overall Survival



Vehicle — 0.3 µg MOR209/ES414* — 3 µg MOR209/ES414* — 5 µg BiTE scFv-scFv*

*$P<0.01$; †$P<0.001$
MOR209/ES414 was dosed on days 0, 4, 8; scFv-scFv molecule dosed daily on days 0-9

ADAPTIR - Novel Preclinical Pipeline

Validated Platform Technology:

- *Bispecific ADAPTIR molecules can redirect T-cell cytotoxicity against multiple tumor targets in preclinical models*

Modular Bispecific Platform:

- *ADAPTIR platform can be used to generate bispecifics with novel MOA in immuno-oncology and other diseases*

Molecule	Target Antigen Type	Target Indication(s)	Development Activity				
			Design	*in vitro* RTCC	*in vivo* POC	Tox/IND	Clinical: Phase 1
αROR1 x αCD3	Tyrosine Kinase (ROR1)	Hematologic malignancies; solid tumors					
RTCC Candidate	Undisclosed target	Hematological malignancies					
Multiple RTCC candidates	Undisclosed targets	Immuno-oncology					
ADAPTIR with Novel MOA	Undisclosed targets	Immuno-oncology					

ADAPTIR RTCC Preclinical Candidate: ROR1

- Targets hematologic malignancies and solid tumors
  - Triple-negative breast cancer
  - Ovarian cancer
  - Non-small cell lung cancer
  - Prostate cancer
  - Kidney cancer
  - CLL and MCL and subset of ALL (with t-1418 translocation)
- Ability to establish rapid clinical POC in heme-onc. Disease and simultaneously test in solid tumors
- Preclinical *in vitro* and *in vivo* proof of concept established
- Improved preclinical PK
- Developing lead candidate

AGENDA

Leadership in Bispecific Antibody Development

- Aptevo Today
- ADAPTIR – Differentiated Bispecific Platform
- Summary

Financial Snapshot

Spin Date: August 1, 2016		
Shares Outstanding	20.2M	9/30/2016
Cash Position	$54M (approx.) $20M $15M	12/31/2016 Emergent Payment – 1/5/2017 MidCap Financial - 2nd tranche option
2015 Revenue	$34M $28M $6M	2015 Pro Forma Total Product Sales Contracts, Grants, Collaborations
2016 Revenue	$27M	9/30/2016 YTD Total Product Sales
2017 Cash Burn	$53M - $58M	Estimated cash burn

Key Milestones – 18-24 Months

Development

- Complete Phase 1 study of MOR209/ES414; advance into Phase 2 development in partnership with MorphoSys
- Complete combination otlertuzumab/ibrutinib study
- Generate new ADAPTIR-based RTCC candidates
- Expand application of ADAPTIR-based candidates into new MOA
- File INDs and advance new preclinical ADAPTIR candidates into the clinic

Operational/Financial

- Capture increased market share of Hemophilia B market with expanded U.S. sales of IXINITY
- Expand ex-US commercial market opportunities through new regulatory filings in select foreign jurisdictions
- Continue current and initiate future partnering discussions around product candidates

Multiple Upcoming Valuation Catalysts

Why Aptevo?

1. Established leadership and capabilities in protein-based therapies for cancer
2. Proprietary, versatile, differentiated ADAPTIR technology platform
3. Broad pipeline of clinical and preclinical development candidates
4. Capital efficient model with commercial product portfolio to support R&D funding
5. Solid financial position with runway into 2018

January 2017

Aptevo Therapeutics

Investor Presentation